{"name":"John L. Villano, MD, PhD","slug":"john-l-villano-md-phd","ticker":"","exchange":"","domain":"","description":"John L. Villano, MD, PhD is a biotechnology company focused on the development of immune checkpoint inhibitors for the treatment of various cancers. The company is currently advancing its lead candidate through Phase 3 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Immune checkpoint inhibitor","genericName":"Immune checkpoint inhibitor","slug":"immune-checkpoint-inhibitor","indication":"Cancer (specific indication not specified in provided information)","status":"phase_3"}]}],"pipeline":[{"name":"Immune checkpoint inhibitor","genericName":"Immune checkpoint inhibitor","slug":"immune-checkpoint-inhibitor","phase":"phase_3","mechanism":"Immune checkpoint inhibitors block inhibitory signals on T cells, allowing the immune system to recognize and attack cancer cells.","indications":["Cancer (specific indication not specified in provided information)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWldoSWFoclNhNE8yZFFZZVEzMjVFcGwwN3kybXJBZFUxbGtMRGNwbU11SHhZUDRVTDJxeVNBcmdZc0diQVZuTW1GcUswSUpjMmprX05Fak5FeFNQNXVpTFNaZ2ZmZUFheDNZbF9FeXFJTU1kRmJVMG5RUFNrQ3JYRWNOejByb1BzcFlWU1hkWjN6SEgzVC1RWjZKNFFxeVB2blFyalBiZkhaalJrbmc?oc=5","date":"2025-09-26","type":"pipeline","source":"The American Journal of Managed Care® (AJMC®)","summary":"Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology - The American Journal of Managed Care® (AJMC®)","headline":"Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology - The American Journal of Managed Ca","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}